Spring Bank Pharmaceuticals, Inc. Information Request Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Spring Bank Pharmaceuticals, Inc. (“Spring Bank” or the “Company”) (NASDAQ: SBPH) to F-Star Therapeutics, Limited (“F-Star”). Under the terms of the merger, Spring Bank will issue shares of common stock to the owners of F-Star, with current holders of Spring Bank common stock controlling approximately 39% of the combined company. Following the closing of the proposed merger, the combined company will be re-named F-Star Therapeutics, Inc. and trade under the ticker symbol “FSTX.”

The Spring Bank merger investigation concerns whether the Board of Spring Bank breached their fiduciary duties to stockholders by agreeing to enter into this transaction and whether the merger undervalues Spring Bank relative to F-Star, thereby harming Spring Bank shareholders.